IN2014CN02971A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02971A IN2014CN02971A IN2971CHN2014A IN2014CN02971A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A IN 2971CHN2014 A IN2971CHN2014 A IN 2971CHN2014A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A
- Authority
- IN
- India
- Prior art keywords
- formula
- compound
- alkyl
- halo
- orn
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- FDKLLWKMYAMLIF-UHFFFAOYSA-N cyclopropane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CC1 FDKLLWKMYAMLIF-UHFFFAOYSA-N 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003880 polar aprotic solvent Substances 0.000 abstract 1
- 150000003512 tertiary amines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549312P | 2011-10-20 | 2011-10-20 | |
| PCT/US2012/061320 WO2013059788A1 (en) | 2011-10-20 | 2012-10-22 | Process for preparing quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02971A true IN2014CN02971A (OSRAM) | 2015-07-03 |
Family
ID=47146705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2971CHN2014 IN2014CN02971A (OSRAM) | 2011-10-20 | 2012-10-22 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9365516B2 (OSRAM) |
| EP (1) | EP2768796B1 (OSRAM) |
| JP (2) | JP6208140B2 (OSRAM) |
| KR (1) | KR102075371B1 (OSRAM) |
| CN (2) | CN104395284A (OSRAM) |
| AR (1) | AR088483A1 (OSRAM) |
| AU (2) | AU2012325768B2 (OSRAM) |
| BR (1) | BR112014009302B1 (OSRAM) |
| CA (1) | CA2852771C (OSRAM) |
| DK (1) | DK2768796T3 (OSRAM) |
| EA (1) | EA031485B1 (OSRAM) |
| ES (1) | ES2765013T3 (OSRAM) |
| GE (1) | GEP20207110B (OSRAM) |
| HU (1) | HUE048023T2 (OSRAM) |
| IL (1) | IL232139A (OSRAM) |
| IN (1) | IN2014CN02971A (OSRAM) |
| MX (1) | MX343288B (OSRAM) |
| PL (1) | PL2768796T3 (OSRAM) |
| PT (1) | PT2768796T (OSRAM) |
| TW (2) | TWI642650B (OSRAM) |
| UA (1) | UA116876C2 (OSRAM) |
| WO (1) | WO2013059788A1 (OSRAM) |
| ZA (1) | ZA201402579B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101862324B1 (ko) | 2010-07-16 | 2018-05-29 | 엑셀리시스, 인코포레이티드 | C-met 조절제 약제학적 조성물 |
| EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| JP2014505109A (ja) | 2011-02-10 | 2014-02-27 | エクセリクシス， インク． | キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| KR20140025496A (ko) | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
| CN103957915A (zh) | 2011-09-22 | 2014-07-30 | 埃克塞里艾克西斯公司 | 治疗骨质疏松症的方法 |
| MX343288B (es) * | 2011-10-20 | 2016-11-01 | Exelixis Inc | Proceso para la preparación de derivados de quinolina. |
| JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス， インク． | 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤 |
| EA033786B1 (ru) | 2013-03-15 | 2019-11-26 | Exelixis Inc | Метаболиты n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида |
| ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| CN104649969B (zh) * | 2013-11-22 | 2019-02-12 | 广东东阳光药业有限公司 | 一种替尼类药物的盐及其制备方法 |
| KR102354963B1 (ko) | 2014-02-14 | 2022-01-21 | 엑셀리시스, 인코포레이티드 | N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법 |
| US10159666B2 (en) | 2014-03-17 | 2018-12-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
| CN106715397B (zh) | 2014-07-31 | 2021-07-23 | 埃克塞里艾克西斯公司 | 制备氟-18标记的卡博替尼及其类似物的方法 |
| JP6892381B2 (ja) | 2014-08-05 | 2021-06-23 | エグゼリクシス， インコーポレイテッド | 多発性骨髄腫を治療するための薬物の組み合わせ |
| CN108026035B (zh) * | 2015-09-02 | 2021-03-30 | 陈昆锋 | 具有蛋白酪氨酸磷酸酶shp-1激动剂活性的化合物 |
| US11141413B2 (en) | 2016-04-15 | 2021-10-12 | Exelixis, Inc. | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
| CN109836382B (zh) * | 2017-11-29 | 2021-11-05 | 江苏豪森药业集团有限公司 | 苹果酸卡博替尼及其中间体的制备方法 |
| PE20211203A1 (es) | 2018-01-26 | 2021-07-05 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| TWI885744B (zh) | 2018-06-15 | 2025-06-01 | 漢達生技醫藥股份有限公司 | 卡博替尼十二烷基硫酸鹽在製備用於治療甲狀腺癌、腎細胞癌或肝細胞癌之劑型的用途 |
| CN112142619B (zh) * | 2020-10-20 | 2023-01-10 | 浙江工业大学 | 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用 |
| AU2022242950A1 (en) * | 2021-03-24 | 2023-11-09 | Biocon Limited | Process for preparation of cabozantinib |
| WO2024111001A1 (en) * | 2022-11-25 | 2024-05-30 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation |
| KR20250136810A (ko) | 2023-01-31 | 2025-09-16 | 한다 온콜로지, 엘엘씨 | 개선된 카보잔티닙 조성물 및 사용 방법 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2210607E (pt) * | 2003-09-26 | 2012-01-31 | Exelixis Inc | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolina-4-ilpropil)oxi]quinolina-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida para o tratamento do cancro |
| WO2006014325A2 (en) * | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| EP1874759A4 (en) | 2005-04-06 | 2009-07-15 | Exelixis Inc | C-MET MODULATORS MODULATORS AND METHODS OF USE |
| CN101605540A (zh) | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| WO2009136663A1 (en) * | 2008-05-08 | 2009-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
| TW201035017A (en) | 2008-09-26 | 2010-10-01 | Smithkline Beecham Corp | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide |
| CN102282134B (zh) * | 2008-11-13 | 2015-04-01 | 埃克塞里艾克西斯公司 | 喹啉衍生物制备方法 |
| JP2012511017A (ja) | 2008-12-04 | 2012-05-17 | エグゼリクシス， インコーポレイテッド | キノリン誘導体の調製方法 |
| BRPI1006812B8 (pt) | 2009-01-16 | 2023-01-24 | Exelixis Inc | Forma cristalina de l-malato de n-(4-{[6,7-bis(metiloxi)-quinolin-4-il]oxi}fenil)-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composições farmacêuticas e usos do mesmo |
| AU2010274012A1 (en) | 2009-07-17 | 2012-02-09 | Exelixis, Inc. | Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy] -quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| SG184040A1 (en) | 2010-03-12 | 2012-10-30 | Exelixis Inc | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| KR101862324B1 (ko) | 2010-07-16 | 2018-05-29 | 엑셀리시스, 인코포레이티드 | C-met 조절제 약제학적 조성물 |
| US20140186407A9 (en) | 2010-07-16 | 2014-07-03 | Exelixis Inc. | C-Met Modulator Pharmaceutical Compositions |
| EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| CN103391773A (zh) | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
| JP2013540759A (ja) | 2010-09-27 | 2013-11-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
| CN103327979A (zh) | 2010-11-22 | 2013-09-25 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 治疗癌症的方法 |
| JP2014505109A (ja) | 2011-02-10 | 2014-02-27 | エクセリクシス， インク． | キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| KR20140025496A (ko) | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
| TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| CN103957915A (zh) | 2011-09-22 | 2014-07-30 | 埃克塞里艾克西斯公司 | 治疗骨质疏松症的方法 |
| MX343288B (es) * | 2011-10-20 | 2016-11-01 | Exelixis Inc | Proceso para la preparación de derivados de quinolina. |
| CA2854336A1 (en) | 2011-11-08 | 2013-05-16 | Exelixis, Inc. | Dual inhibitor of met and vegf for treating cancer |
| JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス， インク． | 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤 |
| CN114129566A (zh) | 2012-09-07 | 2022-03-04 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
-
2012
- 2012-10-22 MX MX2014004583A patent/MX343288B/es active IP Right Grant
- 2012-10-22 TW TW106121791A patent/TWI642650B/zh active
- 2012-10-22 CN CN201280054241.3A patent/CN104395284A/zh active Pending
- 2012-10-22 AU AU2012325768A patent/AU2012325768B2/en active Active
- 2012-10-22 ES ES12783763T patent/ES2765013T3/es active Active
- 2012-10-22 WO PCT/US2012/061320 patent/WO2013059788A1/en not_active Ceased
- 2012-10-22 BR BR112014009302A patent/BR112014009302B1/pt active IP Right Grant
- 2012-10-22 PL PL12783763T patent/PL2768796T3/pl unknown
- 2012-10-22 CN CN201910783833.2A patent/CN110511158A/zh active Pending
- 2012-10-22 CA CA2852771A patent/CA2852771C/en active Active
- 2012-10-22 DK DK12783763.1T patent/DK2768796T3/da active
- 2012-10-22 EP EP12783763.1A patent/EP2768796B1/en active Active
- 2012-10-22 JP JP2014537359A patent/JP6208140B2/ja active Active
- 2012-10-22 EA EA201490831A patent/EA031485B1/ru unknown
- 2012-10-22 US US14/353,251 patent/US9365516B2/en active Active
- 2012-10-22 IN IN2971CHN2014 patent/IN2014CN02971A/en unknown
- 2012-10-22 AR ARP120103944 patent/AR088483A1/es not_active Application Discontinuation
- 2012-10-22 UA UAA201405355A patent/UA116876C2/uk unknown
- 2012-10-22 GE GEAP201213471A patent/GEP20207110B/en unknown
- 2012-10-22 HU HUE12783763A patent/HUE048023T2/hu unknown
- 2012-10-22 TW TW101139005A patent/TWI619694B/zh active
- 2012-10-22 PT PT127837631T patent/PT2768796T/pt unknown
- 2012-10-22 KR KR1020147012435A patent/KR102075371B1/ko active Active
-
2014
- 2014-04-09 ZA ZA2014/02579A patent/ZA201402579B/en unknown
- 2014-04-22 IL IL232139A patent/IL232139A/en active IP Right Grant
-
2016
- 2016-04-20 US US15/133,708 patent/US9969692B2/en active Active
-
2017
- 2017-06-07 JP JP2017112355A patent/JP2017222648A/ja active Pending
- 2017-11-06 AU AU2017254982A patent/AU2017254982A1/en not_active Abandoned
-
2018
- 2018-04-17 US US15/955,246 patent/US20180230100A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02971A (OSRAM) | ||
| MX2014006992A (es) | Disales de acido malonico y metodo para preparar dihaluros de malonilo. | |
| AU2012248061C1 (en) | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | |
| PH12016502334B1 (en) | Method for producing fused heterocyclic compound | |
| IN2014MN01521A (OSRAM) | ||
| EP2681204A4 (en) | SYNTHESIS OF INTERMEDIATE PRODUCTS FOR TREPROSTINE PRODUCTION | |
| IN2014DN00144A (OSRAM) | ||
| NZ601805A (en) | Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same | |
| IN2014MN00976A (OSRAM) | ||
| UA111868C2 (uk) | Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти | |
| PH12011000224A1 (en) | Synthesis of rare earth metal extractant | |
| IN2014CN02346A (OSRAM) | ||
| WO2011102640A3 (en) | Method for preparing sitagliptin and amine salt intermediates used therein | |
| MX2012001722A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| IN2012DN00361A (OSRAM) | ||
| MX2013008595A (es) | Procedimiento mejorado para la preparacion de 2,2-difluoroetilamina. | |
| UA113067C2 (xx) | Спосіб одержання хінолінкарбонової кислоти | |
| IN2014CN04123A (OSRAM) | ||
| UA111329C2 (uk) | Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою | |
| BR112013018809A8 (pt) | Processo para produção de derivados de ácido amidocarboxílico aromático | |
| MX345768B (es) | Procedimiento para la preparación de 2,2-dufluoroetilamina partiendo de un compuesto de bencilamina. | |
| MX2014008995A (es) | Compuesto novedoso de ester de acido acetico o una sal del mismo. | |
| NZ709587A (en) | Method for preparing cyclopropane derivatives | |
| GEP20156369B (en) | New process for synthesis of ivabradine and addition salts therewith pharmaceutically acceptable acid | |
| IN2014DN10440A (OSRAM) |